In the latest session, NeuBase Therapeutics Inc. (NASDAQ: NBSE) closed at $0.20 up 2.60% from its previous closing price of $0.20. In other words, the price has increased by $+0.0138 from its previous closing price. On the day, 896358 shares were traded. NBSE stock price reached its highest trading level at $0.2299 during the session, while it also had its lowest trading level at $0.1900.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
For a deeper understanding of NeuBase Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.40 and its Current Ratio is at 8.40. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 12, 2021, Reiterated its Buy rating but revised its target price to $18 from $15 previously.
On June 16, 2020, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 30 when Mann William Roland bought 6,200 shares for $1.92 per share. The transaction valued at 11,904 led to the insider holds 11,200 shares of the business.
Branning Todd P. bought 10,000 shares of NBSE for $18,100 on Mar 18. The Chief Financial Officer now owns 30,000 shares after completing the transaction at $1.81 per share. On Mar 17, another insider, Branning Todd P., who serves as the Chief Financial Officer of the company, bought 10,000 shares for $1.74 each. As a result, the insider paid 17,400 and bolstered with 20,000 shares of the company.
Stock Price History:
Over the past 52 weeks, NBSE has reached a high of $2.08, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is 0.2449, while the 200-Day Moving Average is calculated to be 0.5018.
Shares Statistics:
For the past three months, NBSE has traded an average of 356.08K shares per day and 218.39k over the past ten days. A total of 33.02M shares are outstanding, with a floating share count of 30.02M. Insiders hold about 2.50% of the company’s shares, while institutions hold 37.20% stake in the company. Shares short for NBSE as of Jan 12, 2023 were 304.37k with a Short Ratio of 0.32M, compared to 318.17k on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.92% and a Short% of Float of 0.98%.
Earnings Estimates
There are 2 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.2, while EPS last year was -$0.24. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.32 and -$0.58 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.33, with 1 analysts recommending between -$0.33 and -$0.33.
